Assess whether the primary endpoint will survive FDA scrutiny (3e9012)

SITUATION The working file is phase-3 protocol with endpoint-sensitivity issues after a boxed-warning proposal from the review division. 505(b)(2) development lead in a mid-size sponsor after a complete response letter has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Clinical and Evidence Strategy file.

DECISION 505(b)(2) development lead in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using phase-3 protocol with endpoint-sensitivity issues after a boxed-warning proposal from the review division.

HYPOTHESES TO TEST 1. The population in phase-3 protocol with endpoint-sensitivity issues is the one a boxed-warning proposal from the review division named, so Proceed under protocol follows for this Clinical and Evidence Strategy file. 2. The population in phase-3 protocol with endpoint-sensitivity issues is adjacent only to a boxed-warning proposal from the review division; Pause the pathway is the honest Pharma & Life Sciences call. 3. A mid-size sponsor after a complete response letter already contained a boxed-warning proposal from the review division before phase-3 protocol with endpoint-sensitivity issues arrived; no new Clinical and Evidence Strategy path. 4. Provenance on phase-3 protocol with endpoint-sensitivity issues after a boxed-warning proposal from the review division is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 3. Check whether phase-3 protocol with endpoint-sensitivity issues supports the labeled claim 505(b)(2) development lead would keep. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read phase-3 protocol with endpoint-sensitivity issues against a boxed-warning proposal from the review division and write the one fact that would move the primary endpoint will for 505(b)(2) development lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (phase-3 protocol with endpoint-sensitivity issues after a boxed-warning proposal from the review division). The follow-on Clinical and Evidence Strategy action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the primary endpoint will, then the evidence in phase-3 protocol with endpoint-sensitivity issues, then the action for 505(b)(2) development lead - Hypothesis scorecard against phase-3 protocol with endpoint-sensitivity issues: supported / rejected / untestable - Owner and next date for 505(b)(2) development lead in a mid-size sponsor after a complete response letter - What changes the primary endpoint will if a boxed-warning proposal from the review division is later withdrawn